Latest News

Filters close
Newswise: Study reveals factors influencing outcomes in advanced kidney cancer treated with immunotherapy
28-May-2020 11:05 AM EDT
Study reveals factors influencing outcomes in advanced kidney cancer treated with immunotherapy
Dana-Farber Cancer Institute

By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.

Newswise: Phyllis F. Cantor Center for Research in Nursing and Patient Care Services awarded two major research grants
Released: 26-May-2020 2:20 PM EDT
Phyllis F. Cantor Center for Research in Nursing and Patient Care Services awarded two major research grants
Dana-Farber Cancer Institute

Nurse-scientists from the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute received more than $1.3 million dollars in funding for two separate research projects.

19-May-2020 8:00 AM EDT
Dana-Farber to test blood cancer drug in COVID-19 patients
Dana-Farber Cancer Institute

Scientists at Dana-Farber Cancer Institute have launched a clinical test of a blood cancer drug in patients infected with the COVID-19 virus.

24-Apr-2020 3:05 PM EDT
Immune system changes occur early in development of multiple myeloma, study finds
Dana-Farber Cancer Institute

Long before multiple myeloma becomes a malignant disease, the collection of immune system cells and signal carriers amid the tumor cells undergoes dramatic shifts, with alterations in both the number and type of immune cells, researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital (MGH) report in a new study.

Newswise: Dana-Farber Cancer Institute faculty recognized as 2020 ASCO leaders in cancer research and care
Released: 24-Apr-2020 4:25 PM EDT
Dana-Farber Cancer Institute faculty recognized as 2020 ASCO leaders in cancer research and care
Dana-Farber Cancer Institute

The American Society of Clinical Oncology (ASCO) recognized four Dana-Farber Cancer Institute researchers as winners of ASCO's Special Awards, the Society’s highest honors. The recipients of these awards have worked to transform cancer care around the world.

21-Apr-2020 2:30 PM EDT
New targeted agent produces considerable responses in trial with patients with uterine serous carcinoma
Dana-Farber Cancer Institute

The DNA repair-blocking drug adavosertib shrinks tumors in nearly one-third of patients in clinical trial. Data will be shared virtually at the Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.

Released: 23-Apr-2020 2:05 PM EDT
SHE Center at Dana-Farber and Silverberry Genomix form SHE Biobank, a Population Health Initiative for Research and Education
Dana-Farber Cancer Institute

Dana-Farber and Silverberry Genomix launch the SHE Biobank initiative -- a long-term study to investigate the impact of genetic predisposition and environmental exposure to development of disease.

Newswise: Massive study reveals how “hypermutated” malignant brain tumors with many mutations escape chemotherapy and immunotherapy
Released: 15-Apr-2020 1:55 PM EDT
Massive study reveals how “hypermutated” malignant brain tumors with many mutations escape chemotherapy and immunotherapy
Dana-Farber Cancer Institute

An analysis of more than 10,000 gliomas and clinical outcomes reported in Nature by scientists in Boston and Paris found that glioma patients whose tumors were hypermutated actually had no significant benefit when treated with checkpoint blockers.

Released: 7-Apr-2020 10:40 AM EDT
Dana-Farber scientists bring experience from SARS and MERS outbreaks to aid COVID-19 research
Dana-Farber Cancer Institute

As scientists race to develop and test new treatments for COVID-19, Dana-Farber’s Wayne Marasco, MD, PhD, and his lab team are bringing one of the world’s most formidable resources to the effort: a “library” of 27 billion human antibodies against viruses, bacteria, and other bodily invaders.The collection, created by Marasco and his associates in 1997 using blood samples from more than 57 Dana-Farber staff, has already had an illustrious history in the quest to tame viral disease outbreaks.

Newswise: New blood test can detect wide range of cancers, now available to at risk individuals in clinical study at Dana-Farber
30-Mar-2020 8:25 AM EDT
New blood test can detect wide range of cancers, now available to at risk individuals in clinical study at Dana-Farber
Dana-Farber Cancer Institute

In a study involving thousands of participants, a new blood test detected more than 50 types of cancer as well as their location within the body with a high degree of accuracy, according to an international team of researchers led by Dana-Farber Cancer Institute and the Mayo Clinic.

Newswise: A case of reverse development: Dana-Farber scientists solve long-debated puzzle of how the intestine heals itself
19-Feb-2020 3:45 PM EST
A case of reverse development: Dana-Farber scientists solve long-debated puzzle of how the intestine heals itself
Dana-Farber Cancer Institute

Scientists find that normal intestinal cells “de-differentiate” en masse into stem cells that generate the cells needed for a healthy intestinal lining. New study establishes de-differentiation as the predominant mode of stem cell recover in the intestine

Newswise: Novel targeted drug shows promise in advanced kidney cancer
Released: 13-Feb-2020 12:45 PM EST
Novel targeted drug shows promise in advanced kidney cancer
Dana-Farber Cancer Institute

Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease.

Released: 11-Feb-2020 10:00 AM EST
Dana-Farber Cancer Institute provides state-of-the-art oncology support services to Kronos employees through new company benefit
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute and Kronos Incorporated have joined forces to provide dedicated oncology care navigation services via a new benefit for Kronos employees and their beneficiaries.

Newswise: Dozens of potential anti-cancer drugs netted in massive screening study
19-Jan-2020 11:05 AM EST
Dozens of potential anti-cancer drugs netted in massive screening study
Dana-Farber Cancer Institute

A variety of existing drugs for treating conditions such as diabetes, inflammation, alcohol abuse, and arthritis in dogs can also kill cancer cells in the lab, according to a study by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.

Newswise: Dana-Farber Cancer Institute to Establish Riney Family Multiple Myeloma Initiative
Released: 13-Jan-2020 9:00 AM EST
Dana-Farber Cancer Institute to Establish Riney Family Multiple Myeloma Initiative
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute will establish the Riney Family Multiple Myeloma Initiative to help improve outcomes and accelerate understanding of the underlying biology for the most challenging types of myelomas, cancers that form in a type of white blood cell called a plasma cell.

Newswise: Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers
3-Jan-2020 3:55 PM EST
Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute’s capabilities for studying and treating lung cancer.

Newswise: Treatment with PD-1 inhibitor prior to stem cell transplant is safe, effective for patients with classic Hodgkin lymphoma, study finds
26-Nov-2019 5:05 PM EST
Treatment with PD-1 inhibitor prior to stem cell transplant is safe, effective for patients with classic Hodgkin lymphoma, study finds
Dana-Farber Cancer Institute

A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma.

Newswise: Dana-Farber scientists present promising findings in multiple myeloma at ASH Annual Meeting
6-Dec-2019 8:30 AM EST
Dana-Farber scientists present promising findings in multiple myeloma at ASH Annual Meeting
Dana-Farber Cancer Institute

Results of studies on a novel agent to treat multiple myeloma and a combination therapy aimed at slowing the progression of a precursor myeloma condition are among reports being presented by Dana-Farber Cancer Institute investigators at the ASH Annual Meeting.

Newswise: Use of venetoclax in reduced-intensity transplant conditioning regimen in patients with high-risk myeloid cancers shows promise in early trial
5-Dec-2019 12:05 PM EST
Use of venetoclax in reduced-intensity transplant conditioning regimen in patients with high-risk myeloid cancers shows promise in early trial
Dana-Farber Cancer Institute

For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients’ bodies, a study led by Dana-Farber Cancer Institute researchers suggests.

Newswise: Genomic features of AML in patients over age 60 can predict success of bone marrow stem cell transplant, research shows
6-Dec-2019 8:30 AM EST
Genomic features of AML in patients over age 60 can predict success of bone marrow stem cell transplant, research shows
Dana-Farber Cancer Institute

For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute and other research centers will report today at the ASH Annual Meeting.

Released: 25-Nov-2019 1:25 PM EST
Dana-Farber researchers to present more than 40 studies at 2019 ASH Annual Meeting
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the 61st American Society of Hematology (ASH) Annual Meeting on December 7-10 in Orlando, Fla.

Newswise: Study finds racial disparities in culturally competent cancer care
30-Oct-2019 1:05 PM EDT
Study finds racial disparities in culturally competent cancer care
Dana-Farber Cancer Institute

Many non-white minority cancer survivors place importance on seeing doctors who share or understand their culture, but are less likely than non-Hispanic whites to be able to see such physicians, according to a new study from Dana-Farber Cancer Institute and University of Texas Southwestern. The study, which is one of the first nationally-representative studies to examine patient-reported preference for, access to, and quality of provider cultural competency among cancer survivors, published in JAMA Oncology.

Released: 28-Oct-2019 12:15 PM EDT
Dana-Farber Cancer Institute launches new national advertising campaign
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is launching a new campaign themed, What We Do Here Changes Lives Everywhere”.

Newswise: William G. Kaelin, MD, of Dana-Farber Cancer Institute wins 2019 Nobel Prize
Released: 7-Oct-2019 8:55 AM EDT
William G. Kaelin, MD, of Dana-Farber Cancer Institute wins 2019 Nobel Prize
Dana-Farber Cancer Institute

William G. Kaelin Jr., MD, of Dana-Farber Cancer Institute, has been named a winner of the 2019 Nobel Prize in physiology or medicine.

Newswise: New blood test capable of detecting multiple types of cancer
25-Sep-2019 10:05 PM EDT
New blood test capable of detecting multiple types of cancer
Dana-Farber Cancer Institute

A new blood test in development has shown ability to screen for numerous types of cancer with a high degree of accuracy, a trial of the test shows.

Released: 26-Sep-2019 3:30 PM EDT
Dana-Farber Cancer Institute and the Jimmy Fund Debut New Visual Identity
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute unveiled a new visual identity today, modernizing its logo and that of the Jimmy Fund.

Newswise: Resistance to immune checkpoint blocker drug linked to metabolic imbalance
Released: 25-Sep-2019 1:05 PM EDT
Resistance to immune checkpoint blocker drug linked to metabolic imbalance
Dana-Farber Cancer Institute

A metabolic imbalance in some cancer patients following treatment with a checkpoint inhibitor drug, nivolumab, is associated with resistance to the immunotherapy agent and shorter survival, report scientists from Dana-Farber Cancer Institute.

Newswise: Chronic insomnia can be cured in cancer survivors with a basic, one-session sleep education class, study finds
12-Sep-2019 3:05 PM EDT
Chronic insomnia can be cured in cancer survivors with a basic, one-session sleep education class, study finds
Dana-Farber Cancer Institute

In a study published online today by the journal Cancer, investigators at Dana-Farber Cancer Institute report that a single-session sleep education program for survivors can cure insomnia in many participants, and that those who don’t benefit from this approach are often helped by a more extensive, but still modest, three-session program.

Newswise: Dana-Farber Cancer Institute receives $5 million gift to create the Edward P. Evans Center for Myelodysplastic Syndromes
16-Sep-2019 11:05 AM EDT
Dana-Farber Cancer Institute receives $5 million gift to create the Edward P. Evans Center for Myelodysplastic Syndromes
Dana-Farber Cancer Institute

A $5 million gift from the Edward P. Evans Foundation will create the Edward P. Evans Center for Myelodysplastic Syndromes (MDS) at Dana-Farber Cancer Institute.

Newswise:Video Embedded dana-farber-cancer-institute-is-awarded-its-fourth-consecutive-designation-as-a-magnet-organization-for-excellence-in-nursing-practice-and-patient-care
VIDEO
Released: 20-Aug-2019 2:45 PM EDT
Dana-Farber Cancer Institute Is Awarded Its Fourth Consecutive Designation as a Magnet® Organization for Excellence in Nursing Practice and Patient Care
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute has been awarded Magnet® status from the American Nurses Credentialing Center (ANCC) for the fourth consecutive time. This prestigious designation recognizes excellence in nursing practice and health care delivery and has been awarded to only 8% percent of hospitals in the United States.

Newswise: Exercise associated with benefit to patients with advanced colorectal cancer
Released: 14-Aug-2019 9:50 AM EDT
Exercise associated with benefit to patients with advanced colorectal cancer
Dana-Farber Cancer Institute

Patients with metastatic colorectal cancer who engaged in moderate exercise while undergoing chemotherapy tended to have delayed progression of their disease and fewer severe side effects from treatment, according to the results of a new study.

Newswise: Inherited pancreatic cancer risk mutation identified
12-Aug-2019 8:35 AM EDT
Inherited pancreatic cancer risk mutation identified
Dana-Farber Cancer Institute

The discovery of the previously unknown mutation, reported in Nature Genetics by investigators from Dana-Farber/Brigham and Women’s Cancer Center, could lead to routine testing of individuals with a strong family history of pancreatic cancer to determine if they carry the mutation, occurring in the gene known as RABL3.

23-Jul-2019 11:05 AM EDT
New AI tool developed by Dana-Farber identifies cancer outcomes using radiology reports
Dana-Farber Cancer Institute

Scientists at Dana-Farber Cancer Institute have demonstrated that an artificial intelligence tool can perform as well as human reviewers – and much more rapidly - in extracting clinical information regarding changes in tumors from unstructured radiology reports for patients with lung cancer.

Newswise: Discovery of pancreatic neuroendocrine subtypes could help predict likelihood of recurrence
Released: 3-Jul-2019 1:05 PM EDT
Discovery of pancreatic neuroendocrine subtypes could help predict likelihood of recurrence
Dana-Farber Cancer Institute

Researchers have discovered two distinct subtypes of pancreatic neuroendocrine tumors – known as pNETs – that have dramatically different risks of recurrence following surgical treatment [or surgery]. The finding could yield predictive tests, ease anxiety in patients whose tumors are found to be unlikely to recur, while focusing vigilant follow-up monitoring on patients with pNETs having a higher rate of recurrence.

Newswise:Video Embedded high-doses-of-60-plus-year-old-chemotherapy-drug-found-to-spur-immune-system-attack-on-lymphoma
VIDEO
28-Jun-2019 3:00 PM EDT
High doses of 60-plus year-old chemotherapy drug found to spur immune system attack on lymphoma
Dana-Farber Cancer Institute

Cyclophosphamide, a mainstay of chemotherapy for many cancers, acts as both chemotherapy and immunotherapy at high doses, study finds

Released: 5-Jun-2019 4:50 PM EDT
Walking Speed Points to Future Clinical Outcomes for Older Patients with Blood Cancers
Dana-Farber Cancer Institute

Researchers at Dana-Farber Cancer Institute and the VA Boston Healthcare System have uncovered a new vital sign for gauging survival and likelihood of having an unplanned hospitalization in older patients with blood cancers: the speed at which they can walk.In a study published today in the journal Blood, the researchers report that for every 0.

Newswise:Video Embedded enzalutamide-improves-survival-for-men-with-metastatic-hormone-sensitive-prostate-cancer
VIDEO
2-Jun-2019 6:30 AM EDT
Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer
Dana-Farber Cancer Institute

Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology (ASCO) Annual Meeting.

Newswise: Pre-surgical immunotherapy shows promise in trial for patients with early stage lung cancer
30-May-2019 2:05 PM EDT
Pre-surgical immunotherapy shows promise in trial for patients with early stage lung cancer
Dana-Farber Cancer Institute

Pre-surgical immunotherapy shows promise in trial for patients with early stage lung cancer

Newswise: Patterns of chronic lymphocytic leukemia growth identified
29-May-2019 12:00 PM EDT
Patterns of chronic lymphocytic leukemia growth identified
Dana-Farber Cancer Institute

In patients with chronic lymphocytic leukemia, the rate of disease growth is apt to follow one of three trajectories: relentlessly upward, steadily level, or something in between, scientists at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, Massachusetts General Hospital, and the University of Washington report in a new study.

Newswise:Video Embedded black-men-less-likely-than-nonblack-patients-to-adopt-active-surveillance-for-low-risk-prostate-cancer
VIDEO
21-May-2019 1:05 PM EDT
Black Men Less Likely Than Nonblack Patients to Adopt Active Surveillance for Low-Risk Prostate Cancer
Dana-Farber Cancer Institute

At a time when a growing number of men with prostate cancer considered “low risk” are opting for active surveillance or watchful waiting rather than immediate treatment with surgery or radiation, a new study reveals that black men are less likely than white men to adopt an active surveillance strategy for their disease.

Newswise: Dana-Farber researchers present findings in more than 70 research studies at ASCO annual meeting 2019
Released: 16-May-2019 3:05 PM EDT
Dana-Farber researchers present findings in more than 70 research studies at ASCO annual meeting 2019
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute researchers are presenting more than 70 research studies at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31st- June 4th. ASCO is the world’s largest clinical cancer research meeting, attracting more than 30,000 oncology professionals from around the world.

23-Apr-2019 11:05 AM EDT
Targeted therapy proves effective against aggressive rare blood cancer
Dana-Farber Cancer Institute

Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease

Newswise: Researchers devise a progression risk-based classification for patients with asymptomatic Waldenström macroglobulinemia
Released: 23-Apr-2019 12:05 PM EDT
Researchers devise a progression risk-based classification for patients with asymptomatic Waldenström macroglobulinemia
Dana-Farber Cancer Institute

Researchers at Dana-Farber Cancer Institute have devised a risk model for determining whether patients with AWM have a low, intermediate, or high risk of developing symptomatic Waldenström macroglobulinemia

Newswise:Video Embedded high-dose-vitamin-d-shows-benefit-in-patients-with-advanced-colorectal-cancer
VIDEO
8-Apr-2019 12:05 PM EDT
High-dose vitamin D shows benefit in patients with advanced colorectal cancer
Dana-Farber Cancer Institute

Results of a small clinical trial suggest that supplementing chemotherapy with high doses of vitamin D may benefit patients with metastatic colorectal cancer by delaying progression of the disease, say scientists from Dana-Farber Cancer Institute.

Released: 27-Mar-2019 1:30 PM EDT
T-Mobile CEO John Legere delivers $4.5 million gift to Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

T-Mobile CEO is giving $4.5 million to support the Profile initiative at Dana-Farber Cancer Institute, one of the broadest and most comprehensive enterprise-level, patient-based cancer genomics projects in the world.

15-Mar-2019 11:05 AM EDT
Adult cells maintain a virtually complete molecular “memory” of their embryonic origins, researchers find
Dana-Farber Cancer Institute

• Study uncovers extensive archive within adult cells of genes active at embryonic stage • Memory can be accessed under certain conditions, making it possible to reactivate fetal genes • Discovery may have major implications for regenerative medicine, cancer research

Newswise: Cigall Kadoch, PhD, chosen for 2019 Wachtel Cancer Research Prize
Released: 15-Mar-2019 9:00 AM EDT
Cigall Kadoch, PhD, chosen for 2019 Wachtel Cancer Research Prize
Dana-Farber Cancer Institute

Dana-Farber researcher Cigall Kadoch, PhD, named recipient of Wachtel Cancer Research Prize

13-Mar-2019 6:05 PM EDT
New study on Serious Illness Care Program underscores significant benefit of more, better, and earlier conversations between clinicians and patients
Dana-Farber Cancer Institute

A new study shows that an innovative communication program developed by Ariadne Labs and tested at the Dana-Farber Cancer Institute resulted in more, earlier and better conversations between patients and their oncology clinicians, and led to significant reductions in emotional suffering for patients with advanced cancer.

Newswise:Video Embedded new-center-addresses-alarming-increase-in-colorectal-cancer-rates-among-young-adults
VIDEO
Released: 5-Mar-2019 9:40 AM EST
New center addresses alarming increase in colorectal cancer rates among young adults
Dana-Farber Cancer Institute

Dana-Farber/Brigham and Women's Cancer Center announced the launch of the Young-Onset Colorectal Cancer Center. The center will provide expert, compassionate and cutting-edge care to young adult colon and rectal cancer patients with a focus on scientific discovery and research.

Newswise: Dana-Farber Opens Center for the Prevention of Progression Clinic
Released: 4-Mar-2019 8:30 AM EST
Dana-Farber Opens Center for the Prevention of Progression Clinic
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute opens Center for the Prevention of Progression clinic to focus on precursor conditions in blood cancers


Showing results

150 of 539

close
0.71804